EUVIMEDEUVIMED entdecken
Crossref

Col10A1 is a Potential Immunotherapy Biomarker Associated With Immune Infiltration and Deficient Mismatch Repair in Colon Cancer

Shuo Cai, Zhiwei Sun, Yan Yan, Weifeng Li, Qi Wu

Immunotherapy · 2023

DOI: 10.2217/imt-2023-0096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy, 2023. Verfasst von Shuo Cai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endoscopy Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospita…. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Science Foundation of Peking University Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Our study aimed to identify the role of COL10A1 in colon cancer, including interaction with immune infiltrates and somatic mutations.

Methods

COL10A1 expression and prognostic value were assessed. Correlations between COL10A1 and various immune parameters were conducted by bioinformatic analysis.

Results

Our study demonstrated that COL10A1 is overexpressed in colon cancer and correlates with poor patient survival. The expression level of COL10A1 is significantly associated with mismatch repair deficiency and immune infiltration. High expression of COL10A1 may confer greater sensitivity to anti-PD-1 treatment in colon cancer patients.

Conclusion

COL10A1 is a potential diagnostic biomarker associated with deficient mismatch repair and immune infiltration in colon cancer. Colorectal cancer (CRC) is a deadly disease and we do not have a cure. Immunotherapy is a new method that can help CRC patients to live longer, but it only works for some people. To find out who will get good results with immunotherapy, we looked at a protein named COL10A1. We found more COL10A1 in colon cancer tissues than in healthy tissues. CRC patients with a lot of COL10A1 are more likely to die than those patients with low levels of this protein. COL10A1 can interact with some immune cells and by looking at how much COL10A1 is in different CRC patients, we may be able to choose the right patients to treat with immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsColorectal NeoplasmsHumansBiomarkers, TumorDNA Mismatch RepairImmunotherapyCollagen Type X

Stichwörter der Autor:innen

COL10A1colon cancerimmune infiltrationimmunotherapymismatch repair deficiency

Substanzen

Biomarkers, TumorCOL10A1 protein, humanCollagen Type X

Autor:innen und Institutionen

  • Department of Endoscopy Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, China.
  • VIP-II Division of Medical Department, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, 100142, China.

Förderung

  • Science Foundation of Peking University Cancer Hospital

Zitieren

APA

Cai, S., Sun, Z., Yan, Y., Li, W., & Wu, Q. (2023). Col10A1 is a Potential Immunotherapy Biomarker Associated With Immune Infiltration and Deficient Mismatch Repair in Colon Cancer. Immunotherapy. https://doi.org/10.2217/imt-2023-0096

Vancouver

Cai S, Sun Z, Yan Y, Li W, Wu Q. Col10A1 is a Potential Immunotherapy Biomarker Associated With Immune Infiltration and Deficient Mismatch Repair in Colon Cancer. Immunotherapy. 2023. doi:10.2217/imt-2023-0096

BibTeX
@article{Cai2023,
  author = {Cai, Shuo and Sun, Zhiwei and Yan, Yan and Li, Weifeng and Wu, Qi},
  title = {Col10A1 is a Potential Immunotherapy Biomarker Associated With Immune Infiltration and Deficient Mismatch Repair in Colon Cancer},
  journal = {Immunotherapy},
  year = {2023},
  doi = {10.2217/imt-2023-0096}
}
Kostenlos starten →